ClinicalTrials.gg
Not yet recruitingNCT07623226Updated Jun 3, 2026

Super-Resolution Ultrasound Imaging for Assessing Response to Neoadjuvant Chemotherapy in Breast Cancer

An observational study in Breast Cancer, sponsored by Anhui Provincial Cancer Hospital. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Anhui Provincial Cancer Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,936 studies in Breast Neoplasms with a site in China — 871 open to participants now, 1,068 under way, 211 of them phase 3. Breast Neoplasms · China.

Planned enrollment
258th of 409
150 · median 240
Started
2026
with 191 others
Observational
409 of 1,936
176 open now
Primary completion
2028-03
later than 820 of 1,067 live
Registered
1,822nd of 1,936
by date

Among the 1,936 studies in Breast Neoplasms with a site in China, this one is the 258th largest by planned enrollment of the 409 observational ones that give a count, is one of 192 that started in 2026, is one of 409 observational ones, reaches primary completion later than 820 of the 1,067 other live ones, and was the 1,822nd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

871 of the 1,936 studies in Breast Neoplasms with a site in China are open now. Recruiting first, the newest first:

866 more — sign in →

All 871 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,936 studies in Breast Neoplasms with a site in China, or all of them as a file.
02

Study summary

  1. Study Design Overview Study Type: Single-center, prospective, observational, diagnostic study. Primary Objective: To validate whether Super-Resolution Ultrasound Imaging (SRUS) can accurately predict pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer at an early stage (after the first cycle of chemotherapy).

    Sample Size: A total of 150 patients are planned to be enrolled. Study Period: March 2026 - March 2028.

  2. Core Methodology: Cohort Allocation This study employs a classic "Model Development-Validation" cohort design to construct a predictive model and verify its generalizability.

    Allocation Method: Systematic random allocation. Allocation Ratio: 7:3. Randomization: Patients will be assigned based on the sequence of enrollment using a computer-generated random sequence.

    Blinding Principle: Allocation information will be concealed (blinded) from patients and the clinical treatment team. Only the research coordinators and statisticians will have access to the grouping data to prevent information leakage.

    Validation Set (Independent Validation Cohort): Comprising 30% of the sample (45 cases). The data will remain "sealed" until model construction is finalized. It will be used for unbiased, objective performance evaluation of the final model (e.g., calculating AUC, sensitivity).

  3. Study Procedures and Visits

    The study workflow strictly adheres to the chemotherapy timeline, with core data collection points focused on the early phase of treatment:

    V0 (Screening): Confirmation of eligibility criteria. V1 (Baseline, Pre-chemotherapy): Initial SRUS examination to acquire baseline tumor data.

    V2 (Early Visit, 48-72 hours after the 1st cycle): The critical data point for the predictive model; the first follow-up examination.

    V3 (Mid-term Visit, Pre-4th cycle): The second follow-up examination. V4 (Surgery, 3-4 weeks after the last cycle): Radical surgery is performed. V5 (Endpoint Assessment, 2-4 weeks post-surgery): Acquisition of pathological results to confirm pCR status (the gold standard).

  4. Key Technology and Statistics Key Technology: The Mindray Resona A20 ultrasound system will be used in conjunction with Sulfur Hexafluoride (SF6) microbubble contrast agents to extract quantitative parameters such as tumor microvascular density and blood volume.

    Statistical Analysis:

    In the Training Set: LASSO regression will be used for feature selection to construct a logistic regression predictive model.

    In the Validation Set: The formula derived from the training set will be directly applied to calculate the Area Under the ROC Curve (AUC), calibration curves, and other metrics to evaluate model performance.

  5. Eligibility Criteria Inclusion Criteria: Females aged 18-75, histologically confirmed invasive breast cancer, scheduled for standard neoadjuvant chemotherapy, with lesions clearly visible on baseline ultrasound.

Exclusion Criteria: History of prior breast cancer treatment (surgery, radiotherapy, chemotherapy), presence of other active malignancies, pregnancy or lactation, severe organ dysfunction, or poor image quality.

Read the detailed description

Background and Rationale Breast cancer is the most common malignancy among women worldwide. Neoadjuvant chemotherapy (NAC) is standard for locally advanced breast cancer, aiming to downstage tumors and increase surgical options. Conventional imaging modalities (ultrasound, MRI) have limitations in detecting early microvascular changes and residual disease. Super-resolution ultrasound imaging (SRUS) is an emerging technique based on ultrasound localization microscopy, enabling visualization of microvasculature at micron-scale resolution. It provides quantitative parameters including vessel density, blood volume, vascular complexity, perfusion index, and intensity analysis. Preliminary evidence suggests SRUS can detect early microvascular alterations before morphological changes become apparent, but prospective data in breast cancer NAC response prediction are lacking.

Study Design Single-center, prospective, observational, diagnostic study. Patients receive standard NAC per clinical guidelines; no treatment intervention is imposed. The study involves additional SRUS examinations at predefined time points.

Model Development and Validation

Consecutive eligible patients are enrolled and randomly assigned (7:3 ratio using computer-generated sequence) to:

Training set (70%, n=105): for model development, feature selection, and internal optimization.

Validation set (30%, n=45): for independent, unbiased performance validation.

Allocation is concealed from patients and clinical care team. Analysis of SRUS images and pathological assessment are blinded to clinical data and group assignment.

Technical Procedures

Equipment: Mindray Resona A20 ultrasound system, probe frequency 5-18 MHz.

Contrast agent: 4.8 mL sulfur hexafluoride microbubbles (SonoVue) injected intravenously, followed by 5 mL saline flush.

Acquisition: Dynamic image sequences (6 seconds each) are acquired during early arterial phase (10-30 s) and late arterial phase (20-45 s) with breath-holding.

Post-processing: SRIPlatform software extracts quantitative parameters: vessel density, blood volume, vascular complexity, perfusion index, intensity, and velocity. Changes from baseline (Δ%) are calculated.

Study Timeline

V1 (Baseline, within 1 week before NAC): Baseline SRUS.

V2 (Early response, 48-72 hours after cycle 1): First follow-up SRUS (key predictive time point).

V3 (Mid-treatment, before cycle 4): Second follow-up SRUS.

V4 (Surgery, 3-4 weeks after last NAC): Radical breast surgery.

V5 (Pathology, 2-4 weeks post-surgery): Pathological complete response (pCR) determination (reference standard).

Sample Size Based on an assumed pCR rate of 30%, a two-sided 95% confidence interval width of 0.15 for sensitivity (expected 80%), 10% dropout, and 30% allocation to validation set, total enrollment is 150 patients. The training set provides \~32 pCR events, supporting evaluation of 3-5 candidate predictors (event-per-variable rule: 10:1).

Statistical Analysis

Software: R 4.3.0 (glmnet, rms, pROC, rmda).

Variable screening: Univariate analysis (p\<0.10), then LASSO regression with 10-fold cross-validation (λ.1se) for dimension reduction.

Model building: Multivariate logistic regression; coefficients, OR, 95% CI.

Internal validation: Bootstrap optimism-corrected AUC.

External validation: Apply final model to validation set; assess discrimination, calibration, and clinical utility (decision curve analysis).

Reporting: Adherence to TRIPOD statement.

Safety and Risk Mitigation SRUS is non-invasive with output within safe limits, equivalent to conventional ultrasound. Risks are minimal (mild discomfort, potential privacy breach). Data are anonymized and stored on encrypted hospital servers.

Quality Control

Standardized operating procedures for image acquisition and post-processing.

Operator training and inter-operator consistency testing.

Image quality review by core laboratory (signal-to-noise ratio, tracking stability, coverage of inflow-washout phases).

100% source data verification for key variables.

Quarterly internal audits.

Ethics and Dissemination Approved by the Institutional Ethics Committee of the First Affiliated Hospital of USTC (West District, Anhui Provincial Cancer Hospital). Conducted in accordance with the Declaration of Helsinki. Written informed consent obtained from all participants. Results will be submitted for publication in peer-reviewed journals regardless of outcome.

Study Period March 2026 - March 2028.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • breast cancer
  • neoadjuvant chemotherapy
  • Super resolution ultrasound imaging
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This study will enroll female patients aged 18 to 75 years with histologically confirmed invasive breast cancer who are scheduled to receive neoadjuvant chemotherapy (NAC) prior to surgery.

Participants must have at least one measurable tumor lesion suitable for super-resolution ultrasound imaging. Patients with evidence of distant metastasis (Stage IV) or those who have received prior systemic therapy for the current cancer diagnosis will be excluded.

The study aims to recruit approximately 150 participants from the Anhui Provincial Cancer Hospital. This population represents a typical cohort of locally advanced breast cancer patients undergoing standard NAC protocols.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age and Gender: Female patients aged 18 to 75 years.
  2. Diagnosis: confirmed invasive breast cancer via core needle .
  3. Treatment Plan: Scheduled to receive standard chemotherapy at our institution.
  4. Imaging: The lesion is clearly visible on baseline ultrasound. Consent: Willing to participate in the study and sign the written form.

Exclusion criteria

Exclusion Criteria

  1. Prior Treatment: History of any prior treatment for ipsilateral breast cancer (e.g., surgery, radiotherapy, chemotherapy, or targeted therapy).
  2. Other : Presence of other active malignancies.
  3. Pregnancy/Lactation: Pregnant or breastfeeding women.
  4. Health Status: Severe cardiac, hepatic, or renal insufficiency, or psychiatric disorders that preclude cooperation with the examination.
  5. Image Quality: Poor ultrasound image quality that prevents SR-US analysis.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Patient registry
No

Groups and cohorts

  • Training set (development queue)

    70% of the total sample size (planned to include 105 cases) will be used for constructing predictive models, feature screening (such as using LASSO regression), and internal optimization.

  • Verification set (independent verification queue)

    Training Set (Development Cohort): Participants assigned to this group constitute 70% of the total sample (n=105). Data from this group are used for model development, feature selection, and internal optimization. Allocation is performed by a computer-generated random sequence (7:3 ratio) at enrollment. The group assignment is concealed from patients and the clinical care team. Validation Set (Independent Validation Cohort): Participants assigned to this group constitute 30% of the total sample (n=45). Data from this group are reserved for unbiased, independent performance validation of the final prediction model. Allocation is performed by a computer-generated random sequence (7:3 ratio) at enrollment. The group assignment is concealed from patients and the clinical care team.

06

What researchers measure

Primary outcomes

  1. Discriminative Ability of the Super-Resolution Ultrasound Prediction Model for Pathological Complete Response (pCR)

    The discriminative ability of the final prediction model (derived from super-resolution ultrasound parameters) in identifying pCR, assessed in the independent validation cohort. Performance is quantified by the Area Under the Receiver Operating Characteristic Curve (AUC). An AUC value closer to 1 indicates stronger discriminative ability.

    Time frame: Through study completion, an average of 24 weeks

Secondary outcomes

  1. Diagnostic performance of the model.

    In the validation set, the optimal cutoff value is determined using the Youden index. Performance metrics including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) are calculated.

    Time frame: Through study completion, an average of 24 weeks

  2. Predictive value of early parameter changes.

    The ability of early changes in super-resolution ultrasound parameters (measured after the first chemotherapy cycle) to predict final pCR status. Evaluated using univariate ROC analysis to calculate the AUC.

    Time frame: 3 weeks

  3. Diagnostic Accuracy, Sensitivity, and Specificity of SRUS Model for pCR

    The secondary outcomes include the diagnostic accuracy, sensitivity, and specificity of the SRUS prediction model. These metrics will be calculated based on the confusion matrix derived from the independent validation cohort.

    Time frame: Through study completion, an average of 24 weeks

  4. Clinical utility of the model.

    The net clinical benefit of using the prediction model to guide clinical decision-making, assessed across a range of threshold probabilities. Evaluated using Decision Curve Analysis (DCA).

    Time frame: Through study completion, an average of 24 months

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Mar 2028, 21 months later.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 21 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2026
First posted
Jun 3, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Mar 1, 2028
CompletionEst.
Jul 1, 2028
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07623226
Lead sponsor
Anhui Provincial Cancer Hospital
Responsible party
Wang Xiaojing (Chief Physician., Anhui Provincial Cancer Hospital) — Principal investigator
First posted
Jun 3, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Mar 1, 2028 (estimated)
Completion
Jul 1, 2028 (estimated)
Last update
Jun 3, 2026

Study contacts

Yang Yang, MD
Contact
yangyang5363@163.com
+8615856969563

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion